Australia markets closed

Biohaven Ltd. (BHVN)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
47.24-2.26 (-4.57%)
At close: 04:00PM EST
47.99 +0.75 (+1.59%)
Pre-market: 04:09AM EST

Biohaven Ltd.

215 Church Street
New Haven, CT 06510
United States
203 404 0410
https://www.biohaven.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees202

Key executives

NameTitlePayExercisedYear born
Dr. Vladimir Coric M.D.Chairman & CEO1.85MN/A1971
Mr. Matthew ButenChief Financial Officer939.45kN/A1961
Dr. Bruce D. Car DACVP, Ph.D.Chief Scientific Officer646.89kN/A1962
Ms. Deb YoungDirector of Regulatory Affairs & OperationsN/AN/AN/A
Mr. George C. ClarkVP & Chief Accounting OfficerN/AN/A1984
Ms. Jennifer PorcelliVice President of Investor RelationsN/AN/AN/A
Mr. Warren Volles J.D.General Counsel & Chief Legal OfficerN/AN/AN/A
Mr. Clifford Bechtold M.S.President, GM of Biohaven Ireland & Chief Compliance OfficerN/AN/AN/A
Ms. Kimberly GentileSenior Vice President of Clinical OperationsN/AN/A1966
Mr. John TiltonChief Commercial Officer of Rare DiseasesN/AN/A1968
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Biohaven Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States. The company's pipeline products include BHV-7000, a potassium channel activator for the treatment of focal epilepsy; BHV-7010, a Kv7 channel modulator for the treatment of different neurological diseases; Troriluzole, a tripeptide prodrug that is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500, a low-trapping glutamate N-methyl-D-aspartate receptor antagonist for neuropathic pain; and Verdiperstat, an oral myeloperoxidase inhibitor, which is in Phase 3 clinical trial for the treatment of neurodegenerative diseases. It also offers Taldefgrobep Alfa, an anti-myostatin adnectin, which is in Phase 3 clinical trial for the treatment of spinal muscle atrophy; and BHV-1100 that is in Phase 1a/1b clinical trial for multiple myeloma patients. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut. Biohaven Ltd. is a subsidiary of Biohaven Pharmaceutical Holding Company Ltd.

Corporate governance

Biohaven Ltd.’s ISS governance QualityScore as of 1 February 2024 is 5. The pillar scores are Audit: 4; Board: 6; Shareholder rights: 3; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.